PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
10.39%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 1.70%. Joel Greenblatt would investigate if growth quality matches quantity.
10.61%
Cost growth of 10.61% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
9.46%
Gross profit growth exceeding 1.5x Medical - Pharmaceuticals median of 2.63%. Joel Greenblatt would investigate competitive advantages.
-0.85%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
41.18%
Other expenses change of 41.18% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
9.34%
Operating expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 4.03%. Jim Chanos would check for waste.
10.42%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 4.01%. Jim Chanos would check for waste.
-5.26%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
35.88%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 0.81%. Jim Chanos would check for overinvestment.
12.20%
EBITDA growth 1.25-1.5x Medical - Pharmaceuticals median of 9.41%. Mohnish Pabrai would examine sustainability.
1.64%
EBITDA margin growth near Medical - Pharmaceuticals median of 1.64%. Charlie Munger would verify industry dynamics.
9.85%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 5.54%. Joel Greenblatt would investigate advantages.
-0.49%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
11.03%
Other expenses change of 11.03% versus flat Medical - Pharmaceuticals. Walter Schloss would verify control.
9.95%
Income change of 9.95% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-0.40%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-0.84%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
20.61%
Net income growth exceeding 1.5x Medical - Pharmaceuticals median of 6.04%. Joel Greenblatt would investigate advantages.
9.26%
Margin change of 9.26% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
20.62%
EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 10.00%. Joel Greenblatt would investigate advantages.
20.62%
Diluted EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 11.59%. Joel Greenblatt would investigate advantages.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate strategy.
No Data
No Data available this quarter, please select a different quarter.